Unable or unwilling to provide informed consent

Vulnerable study populations

Active systemic infection

Diabetes mellitus diagnosis

Preexisting Erectile Dysfunction or urinary incontinence

Metastatic or locally advanced prostatic adenocarcinoma on preoperative evaluation

Men found grossly or pathologically to have locally advanced or metastatic disease at the time of radical prostatectomy

An estimated blood loss of \> 750 mL at the time of radical prostatectomy

Treatment prior to surgery with any form of hormones, anti-androgens or androgen deprivation therapy

Use of an antidepressant, beta blocker or erectile dysfunction medication at the time of study screening

Men without a regular sexual partner

Use of aspirin or heparin 2 weeks before radical prostatectomy

Need for use of aspirin or heparin for 2 weeks or more after radical prostatectomy

Platelet Rich Plasma During Radical Prostatectomy